Yann Mazabraud
Vermogen: 7 M $ op 30-06-2026
Vermogen: 7 M $ op 30-06-2026
Yann Mazabraud is Executive Vice President & Head-International at Rhythm Pharmaceuticals, Inc. since 2020.
Former roles include General Manager-US & Head-North America at Genzyme Corp.
from 2016 to 2017, Head-Latin America at Genzyme Therapeutics Ltd., and Chief Commercial Officer & Head-International at Trevi Therapeutics, Inc. from 2017 to 2020.
Education includes a graduate degree from Groupe de Sup de Co La Rochelle.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 27-04-2026 | 66.030 ( 0,1% ) | 7 M $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05-10-2020 |
| Bedrijven | Functie | Einde |
|---|---|---|
| TREVI THERAPEUTICS, INC. | Corporate Officer/Principal | 03-10-2020 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | 01-10-2017 |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and supplies peptide therapeutics for rare neuroendocrine diseases | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Groupe de Sup de Co La Rochelle
Groupe de Sup de Co La Rochelle Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment for cough conditions | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau